Key Takeaways GEHC beat Q4 EPS and revenue estimates, with 7.1% reported sales growth and a 1.06x book-to-bill.GEHC saw growth in Imaging, AVS and PDx, while Patient Care Solutions revenues fell year over year.Net income margin fell 320 bps from tariffs and mix, even as volume and pricing benefits aided.GE HealthCare (GEHC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.43 by 0.7%. However, the bottom line declined 0.7% year over year.G ...

Core Insights - GE HealthCare (GEHC) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.07, exceeding the Zacks Consensus Estimate of $1.05 by 1.9%, although the EPS declined 6.1% year over year [1][7] - Revenues reached $5.14 billion, reflecting a 6% year-over-year increase on a reported basis and a 4% organic growth, surpassing estimates by 1.4% [2][7] - The company updated its 2025 EPS guidance to a range of $4.51-$4.63, accounting for approximately 45 cents of unfavorable impact from tariffs [9][10] Revenue Details - Total revenues of $5.14 billion were driven by strong performance in the U.S. and EMEA markets, with total company orders increasing 6% organically year over year [2][7] - The revenue growth was supported by the Imaging and Pharmaceutical Diagnostics segments, which offset weaknesses in Patient Care Solutions [7][10] Segmental Performance - Imaging segment revenues totaled $2.35 billion, up 5% year over year, while segment EBIT decreased by 16% to $240 million [3] - Advanced Visualization Solutions generated $1.3 billion in revenues, a 7% increase year over year, with EBIT rising 17% to $271 million [4] - Patient Care Solutions saw revenues of $731 million, down 6% year over year, with EBIT declining 67% to $27 million [3][4] Financial Position - GEHC ended the third quarter with cash, cash equivalents, and investments totaling $4.03 billion, an increase from $3.76 billion in the previous quarter [6] - Total assets rose to $36.13 billion from $35.5 billion sequentially [8] Margins and Cash Flow - The net income margin was 8.7%, down 100 basis points from the prior year, influenced by tariffs but partially offset by volume and price benefits [5] - Cumulative cash flow from operating activities was $937 million, down from $1.04 billion a year ago [5] Strategic Outlook - Continued investment in R&D and new product introductions, including advanced imaging systems and AI-enabled diagnostics, reflects GE HealthCare's commitment to innovation [11] - The company is focused on operational efficiency and disciplined pricing to mitigate cost pressures, indicating strong customer confidence [12]